Walking speed and subclinical atherosclerosis in healthy older adults: the Whitehall II study

Mark Hamer,¹ Mika Kivimaki,¹ Avijit Lahiri,² Ajay Yerramasu,² John E Deanfield,³ Michael G Marmot,¹ Andrew Steptoe¹

ABSTRACT

Objective Extended walking speed is a predictor of incident cardiovascular disease (CVD) in older individuals, but the ability of an objective short-distance walking speed test to stratify the severity of preclinical conditions remains unclear. This study examined whether performance in an 8-ft walking speed test is associated with metabolic risk factors and subclinical atherosclerosis.

Design Cross-sectional.

Setting Epidemiological cohort.

Participants 530 adults (aged 63±6 years, 50.3% male) from the Whitehall II cohort study with no known history or objective signs of CVD.

Main outcome Electron beam computed tomography and ultrasound was used to assess the presence and extent of coronary artery calcification (CAC) and carotid intima-media thickness (IMT), respectively.

Results High levels of CAC (Agatston score >100) were detected in 24% of the sample; the mean IMT was 0.75 mm (SD 0.15). Participants with no detectable CAC completed the walking course 0.16 s (95% CI 0.04 to 0.28) faster than those with CAC ≥400. Objectively assessed, but not self-reported, faster walking speed was associated with a lower risk of high CAC (odds ratio 0.62, 95% CI 0.40 to 0.96) and lower IMT (β=−0.04, 95% CI −0.01 to −0.07 mm) in comparison with the slowest walkers (bottom third), after adjusting for conventional risk factors. Faster walking speed was also associated with lower adiposity, C-reactive protein and low-density lipoprotein cholesterol.

Conclusions Short-distance walking speed is associated with metabolic risk and subclinical atherosclerosis in older adults without overt CVD. These data suggest that a non-aerobically challenging walking test reflects the presence of underlying vascular disease.

Performance on extended walking tests predicts total mortality and incident cardiovascular disease (CVD) in older individuals,¹ but the ability of short-distance walking speed to stratify the severity of subclinical CVD remains uncertain. Several non-invasive imaging techniques can be employed to examine the extent of subclinical atherosclerosis,² ³ which precedes CVD. In a study of 387 healthy, older participants from the Cardiovascular Health Study, coronary artery calcification (CAC) was inversely related to objectively measured walking speed in women but such an association was not seen in men.⁴ In the Three-City study, carotid intima-media thickness (IMT), another proxy measure of subclinical atherosclerosis, was inversely associated with objectively measured maximum walking speed.⁵ In the Multi-Ethnic Study of Atherosclerosis self-reported brisk walking pace was associated with lower CAC and IMT in men but only IMT in women.⁶

Short-distance tests of walking speed compared with those of long-distance and maximum walking speed have several advantages. They can be performed using relatively little clinic space, they are particularly safe and easy to administer, and are not aerobically demanding for the participant. We are not aware of any large-scale studies that have examined the ability of a short-distance walking speed test to capture variation in multiple markers of preclinical atherosclerosis. The aim of the present study was therefore to examine whether the performance in an 8-ft walking speed test is associated with metabolic risk factors and subclinical atherosclerosis, assessed from both CAC and carotid IMT among older men and women with no overt CVD. A second aim was to compare the predictive utility of the objective walking test with that of self-reported walking pace.

METHODS

Participants
A subsample of participants from phase 7 (2003–4) of the Whitehall II epidemiological cohort¹ were recruited for the assessment of CAC in 2006–8. The inclusion criteria for the study were no history or objective signs of coronary heart disease, verified by clinical examination including ECG, and no previous diagnosis or treatment for hypertension or diabetes, inflammatory diseases (including arthritis), or allergies. Thirteen participants (2.4%) were prescribed lipid-lowering medication (statins). Volunteers were of white European origin, aged 53–76 years, and 56.5% were in full-time employment. Selection was stratified by grade of employment (current or most recent) to include higher and lower socioeconomic status participants. From the initially invited 1169 participants, 523 (27.6%) were not eligible (mainly because of prescribed antihypertensive medications) and 303 (25.9%) declined to take part. A higher proportion of participants from lower work grades declined to take part compared with higher grades, (38.6% vs 20.3%, respectively). Participants were prohibited from using any anti-histamine or anti-inflammatory medication 7 days before testing, and were rescheduled if they reported colds or other infections on the day of testing. Participants gave full informed consent to participate in the study and ethical approval was obtained from the UCLH committee on the ethics of human research.
Clinical assessment
Details of the Whitehall II phase 7 clinical assessment are published elsewhere. Walking speed was measured by a trained nurse over a clearly marked 8-ft walking course using a standardised protocol. Participants were either low-heeled close-fitting footwear or walked barefoot. Before the test, participants were shown the walking course and asked to ‘walk to the other end of the course at your usual walking pace, just as if you were walking down the street to go the shops. Walk all the way past the other end of the tape before you stop.’ The starting position was standing with both feet together at the start of the course. Participants were asked to begin walking when properly positioned. The stopwatch was started as the participant’s foot hit the floor across the starting line. Nurses walked behind and to the side of the participant and stopped timing when the participant’s foot hit the floor after the end of the walking course. The test was repeated three times, and performance time on the last walk was used for the present analyses. We also calculated coefficient of variation of the three walks for each participant. Participants reported habitual physical activity from a 20-item questionnaire, a question about usual walking pace (slow/average/brisk/fast), current smoking levels, weekly alcohol intake (units per week) and self-rated health (excellent/very good/good/fair/poor). The physical function scale from the medical outcomes study short-form 36 health survey (SF-36) was used to assess activities of daily living. Respondents were asked about limitations to everyday activities such as lifting, climbing stairs and walking. Scores can range from 0 to 100, with lower scores indicating greater impairment. Anthropometric measures were recorded in light clothing for the calculation of body mass index (BMI), and body fat percentage was measured using a bio-impedance device (BodyStat 1500 Medical, UK). Fasting venous blood samples were taken for the analysis of C-reactive protein (CRP), which was performed using high-sensitivity ELISA (R&D Systems, Oxford, UK), and total and high-density lipoprotein (HDL) cholesterol and triglycerides, which were measured within 72 h in serum stored at 4°C using enzymatic colorimetric methods. Low-density lipoprotein (LDL) cholesterol was derived using the Friedewald equation. Glucose homeostasis was assessed from fasting glucose.

Markers of subclinical atherosclerosis
The assessment of CAC was performed using electron beam computed tomography (GE Imatron C-150; San Francisco, California, USA) as previously described. In brief, 40 contiguous 3-mm slices were obtained during a single breath-hold starting at the carina and proceeding to the level of the dia-phragm. Scan time was 100 ms/slice, synchronised to 40% of the R-R interval. Agatston and volumetric calcium scores were calculated to quantify the extent of CAC by a single experienced investigator blinded to the clinical data on an Aquarius workstation (TeraRecon Inc, San Mateo, California, USA). Carotid IMT was measured using ultrasound scanning.3 The right and left common carotid arteries were scanned with a 5–10-MHz probe (Aloka Prosound 2000, Tokyo, Japan). The carotid bulb was identified, and longitudinal two-dimensional ultrasono-graphic images of the common carotid artery 1–2 cm proximal to the carotid bulb were obtained. The optimal longitudinal image was acquired on the R-wave of the ECG and continuously recorded on video tape for 5 s. Measurements of the posterior wall of the artery were made from stored images with electronic calipers. Carotid IMT was calculated as the distance between the first bright light (lumen–intima interface) and the leading edge of the second bright light (media–adventitia interface). The three maximum measures from the right carotid artery in three different frames and the three maximum measures from the left common carotid artery in three different frames were averaged.

Statistical analysis
Thirteen participants with missing data (n=6 walking test, n=7 bloods) were excluded from all analyses. Walking speed was stratified into three equal sex-specific groups, denoting fast (<1.75 s), medium (1.75–2.10 s; men, 1.73–1.94 s) and slow (women >2.10 s, men >1.94 s). Walking speed variability was also stratified into three equal groups, denoting low (<5%), medium (5–8%), high (>8%). Because of the skewed distribution, CAC was dichotomised and multivariate logistic regression analyses were employed to examine the association of walking speed and variability with the presence of high CAC (Agatston score ≥100). This threshold was based on previous data that demonstrated maximum sensitivity and specificity for detecting cardiovascular events at a threshold calcium score of 100 or greater.12 We calculated odds ratios (OR) and 95% CI for the risk of high CAC according to objectively measured and self-reported walking speed categories, adjusting for age, sex, employment grade (as a marker of social position), smoking, SF-36, statins and conventional risk factors, including BMI, systolic blood pressure, LDL and HDL cholesterol, fasting glucose and CRP. Since the majority of participants reported ‘average’ or ‘brisk’ walking pace we constructed two categories consisting of ‘slow/average’ and ‘brisk/fast’ pace. For consistency the objectively measured walking speed was also split into two categories for these analyses, representing the bottom third (slowest) and upper two-thirds (medium/fast pace). We employed general linear models to examine associations of walking speed with carotid IMT, making the same adjustments as stated above. General linear models were also employed to examine associations of walking speed with metabolic risk markers, including BMI and body fat, systolic blood pressure, total, HDL and LDL cholesterol, log-transformed CRP and fasting glucose. All analyses were conducted using SPSS version 15.

RESULTS
The sample consisted of 530 participants (284 men, 246 women, mean±SD age 63±6 years). Participants had moderately raised cholesterol, but generally demonstrated low risk factors with low rates of smoking and obesity and normal blood pressure (table 1). None of the participants rated their health as ‘poor’, with 68% of the sample giving ratings of ‘excellent’ or ‘very good’. The time taken to complete the walking test ranged from 1.0 to 3.5 s and the average coefficient of variation between tests was 6.7%. Faster walkers were slightly younger, more likely to come from higher work grades, record higher scores on the SF-36 (better physical function) and report better health (table 1). In addition, faster walking speed was associated with lower adiposity, CRP and LDL cholesterol after adjusting for age (see table 1). Blood pressure levels and fasting glucose were unrelated to walking speed. Participants who reported a usual walking pace of ‘brisk/fast’ demonstrated faster walking times (age and sex-adjusted mean difference −0.15, 95% CI −0.21 to −0.08 s) compared with those reporting ‘slow/average’ walking pace. In addition, participants with higher self-reported physical health (top third of SF-36 scores) had marginally faster walking times (age and sex-adjusted mean difference −0.07, 95% CI −0.15 to 0.01 s) than those in the lowest third.

High levels of CAC (Agatston score ≥100) were detected in 24% of the sample. The association between self-reported and objectively assessed walking pace is shown in table 2. Objectively
assessed (but not self-reported) faster walking speed was associated with a lower risk of high CAC after adjustment for potential confounders, OR 0.62 (95% CI 0.40 to 0.96) for the fastest (upper two-thirds) versus slowest (bottom third) walkers. Using linear analyses there was a marginal association between the log-transformed Agatston score and continuous walking time (age and sex adjusted β = 0.049, 95% CI −0.04 to 1.02), indicating a greater extent of CAC in slower walkers. On average, there was a difference of 0.16 s (95% CI 0.04 to 0.28) in the time to complete the walking course in participants with no detectable CAC compared with those with CAC of 400 or greater (see figure 1). Objectively assessed faster walking speed was also associated with lower IMT (β = −0.034, 95% CI −0.002 to −0.067 mm) in comparison with the slowest walkers (bottom third), after adjusting for age, sex, social status, smoking, SF-36 and conventional risk factors (figure 2). No sex differences were observed in these associations (eg, p = 0.64 for sex interaction with walking speed and CAC). High walking variability (top third) was not a significant predictor of CAC (age and sex adjusted OR 1.28, 95% CI 0.76 to 2.18) or IMT (β = −0.008, 95% CI −0.041 to 0.025 mm) in comparison with low walking variability (bottom third).

Table 2  Logistic regression of objective and self-reported walking pace on risk of CAC of 100 or greater

<table>
<thead>
<tr>
<th>Walking pace</th>
<th>Model 1</th>
<th>Model 2</th>
<th>Model 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Objective</td>
<td>OR (95% CI)</td>
<td>OR (95% CI)</td>
<td>OR (95% CI)</td>
</tr>
<tr>
<td>Slowest</td>
<td>1.00 (0.40 to 0.92)</td>
<td>1.00 (0.40 to 0.94)</td>
<td>1.00 (0.40 to 0.96)</td>
</tr>
<tr>
<td>p Value</td>
<td>0.01</td>
<td>0.03</td>
<td>0.03</td>
</tr>
<tr>
<td>Brisk/fast</td>
<td>0.61 (0.40 to 0.92)</td>
<td>0.61 (0.40 to 0.94)</td>
<td>0.62 (0.40 to 0.96)</td>
</tr>
<tr>
<td>Self-reported</td>
<td>0.44</td>
<td>0.59</td>
<td>0.77</td>
</tr>
<tr>
<td>Slow/average</td>
<td>1.00 (0.54 to 1.31)</td>
<td>0.88 (0.56 to 1.39)</td>
<td>0.93 (0.58 to 1.50)</td>
</tr>
<tr>
<td>p Value</td>
<td>0.44</td>
<td>0.59</td>
<td>0.77</td>
</tr>
</tbody>
</table>

Model 1 adjusted for age and sex. Model 2 with further adjustment for employment grade and smoking. Model 3 with further adjustment for systolic blood pressure, low-density lipoprotein and high-density lipoprotein cholesterol, C-reactive protein, fasting glucose, body mass index, short-form 36 score, lipid-lowering medication.

*Slowest third consists of women with walking time greater than 2.10 s and men greater than 1.94 s.

CAC, coronary artery calcification; OR, odds ratio.

DISCUSSION

The present study examined the association of walking speed with markers of subclinical atherosclerosis, assessed from both CAC and carotid IMT, in a sample of older adults without overt CVD. Faster pace walking speed assessed with a short-distance test was associated with a lower prevalence and extent of CAC and lower IMT values, independently of age and other CVD risk factors. These associations were not observed when using the self-reported measure of walking pace. In a recent analysis of the full Whitehall II cohort that employed the short-distance test, age-adjusted walking speed was approximately 15% higher in the highest employment grade compared with the lowest, although our findings suggest that associations with subclinical atherosclerosis are independent of social status. We also observed an association between walking speed and several markers of metabolic health. Repeatable findings across two independent measures of preclinical atherosclerosis and consistent associations with atherosclerosis risk factors suggest that the association between walking speed and preclinical atherosclerosis was robust.

CAC has been shown to be independently predictive of CHD risk over and above traditional cardiac risk factors, and thus may be important in the early detection of atherosclerosis. Our findings extend those reported in the few previous smaller-scale...
studies of objective walking speed and CAC. In community-based samples of healthy elderly participants, walking speed over a 15-ft course was inversely related to CAC in women but not men, and maximum walking pace was inversely associated with carotid plaques and IMT. Our findings are consistent with the evidence that demonstrated associations of objective walking speed with incident CVD and total mortality. Other data have shown an association between impaired physical performance and inflammatory markers in the elderly.

Studies examining the association between self-reported measures of physical activity and CAC have generally produced inconsistent findings, which may be explained by differences in physical activity assessment techniques between studies and limitations of self-reported instruments. In a recent study self-reported brisk walking pace was associated with lower CAC and IMT in men but only IMT in women, which contrasts with our results that showed no associations.

MECHANISMS
As the study was cross-sectional, we cannot determine the directionality of the association between walking speed and preclinical atherosclerosis. Slow walking speed is related to lack of physical exercise, which is a well-established CVD risk factor, and studies have demonstrated that physical inactivity in mid-life can predict functional decline in older age. Therefore, the inverse association of walking speed and subclinical atherosclerosis in older age may reflect cardioprotective effects of physical fitness and suggest that slow walking speed is an antecedent to CVD rather than a consequence. Recent data have confirmed strong inverse associations of exercise capacity, chronotropic response and abnormal heart recovery during exercise stress testing with CAC burden. Given that our objective measure of walking speed was closely associated with self-reported usual walking pace, this might reflect a simple objective measure of habitual physical activity and fitness. Nevertheless, self-reported walking pace in itself was not a robust predictor of subclinical atherosclerosis. Controlled training studies in elderly participants have demonstrated improvements in various metabolic risk factors, including inflammatory markers and insulin sensitivity. However, experimental studies that examine the effects of improved physical function on markers of subclinical atherosclerosis are required.

Alternatively, subclinical vascular factors may play a role in motor function, with slow walking speed reflecting functional consequences of underlying long-term conditions not yet apparent clinically. One hypothesis is that individuals with preclinical atherosclerosis have increased cerebral white matter hyperintensities, a condition that is associated with impaired physical function, including slower gait speed. This hypothesis would imply an association between walking speed and blood pressure, because hypertension, in addition to age, is the main risk factor for white matter hyperintensities. However, walking speed was not associated with systolic blood pressure and was only marginally associated with self-reported physical function in the present study. In addition, high walking variability has been associated with cognitive and functional status and subclinical brain vascular abnormalities, although walking variability was not a predictor of subclinical atherosclerosis in the present study. Nevertheless, other important mechanisms may also be involved. For example, cardiac abnormalities such as impaired left ventricular function that has been associated with subclinical atherosclerosis, may partly explain reduced physical capacity. Subclinical disease of the blood vessels in the legs might lead to discomfort when walking, even though claudication is not present, resulting in a slower pace. Since the walking test is conducted from a standing start this may be another important aspect that is not captured in walking speed per se. This might partly explain the weak associations with self-reported walking pace because it does not take into account factors such as the initiation of movement.

CONCLUSION
The present findings have demonstrated the value of a simple short-distance walking test in capturing the severity of subclinical conditions in older adults not apparent in measures of clinical CVD. We measured walking speed with an 8-ft test in contrast to other studies that have generally employed longer walking distances or assessed maximal walking pace. The main difference in using a short-distance walking test is that it probably does not reflect aerobic capacity and the advantage is that it requires little space and is safe and easy to administer. The short-distance test is thus able to detect differences in subclinical atherosclerosis and is also highly practical, making it a potentially attractive measure for office-based use in clinical practice.

Acknowledgements The authors acknowledge the contributions of the Whitehall II team to data collection, the staff of the Cardiovascular Imaging and Research Centre, Wellington Hospital, London, for performing electron beam computed tomography scans and the Vascular Physiology Unit, University College London, for performing IMT measures.

Funding This research was supported by the British Heart Foundation, UK (RG 05/006).

Competing interests None.

Ethics approval This study was conducted with the approval of the University College London Hospital committee on the ethics of human research.

Patient consent Obtained.

Provenance and peer review Not commissioned; externally peer reviewed.

REFERENCES
Walking speed and subclinical atherosclerosis in healthy older adults: the Whitehall II study

Mark Hamer, Mika Kivimaki, Avijit Lahiri, Ajay Yerramasu, John E Deanfield, Michael G Marmot and Andrew Steptoe

Heart 2010 96: 380-384 originally published online December 1, 2009
doi: 10.1136/hrt.2009.183350

Updated information and services can be found at:
http://heart.bmj.com/content/96/5/380

These include:

References
This article cites 27 articles, 12 of which you can access for free at:
http://heart.bmj.com/content/96/5/380#BIBL

Open Access
This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non-commercial and is otherwise in compliance with the license. See: http://creativecommons.org/licenses/by-nc/2.0/ and http://creativecommons.org/licenses/by-nc/2.0/legalcode.

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections
Open access (237)
Clinical diagnostic tests (4779)
Epidemiology (3752)
Drugs: cardiovascular system (8842)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/